Teva Files 2012 Annual Report on Form 20-F Business Wire JERUSALEM -- March 8, 2013 In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912 or 011-972-3-926-7656. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Contact: Teva Pharmaceutical Industries Ltd. IR: United States Kevin C. Mannix, 215-591-8912 Kristen Frank, 215-591-8908 or Israel Tomer Amitai, 972 (3) 926-7656 or PR: Israel Hadar Vismunski-Weinberg, 972 (3) 926-7687 or United States Denise Bradley, 215-591-8974
Teva Files 2012 Annual Report on Form 20-F
Press spacebar to pause and continue. Press esc to stop.